4.65
price down icon5.32%   -0.2614
pre-market  Pre-market:  4.60   -0.05   -1.08%
loading
Titan Pharmaceuticals Inc De stock is traded at $4.65, with a volume of 77,320. It is down -5.32% in the last 24 hours and up +21.41% over the past month. Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
See More
Previous Close:
$4.9114
Open:
$4.85
24h Volume:
77,320
Relative Volume:
1.83
Market Cap:
$4.21M
Revenue:
$61,000
Net Income/Loss:
$-5.46M
P/E Ratio:
-0.711
EPS:
-6.54
Net Cash Flow:
$-6.76M
1W Performance:
+1.09%
1M Performance:
+21.41%
6M Performance:
+24.00%
1Y Performance:
-29.47%
1-Day Range:
Value
$4.50
$4.915
1-Week Range:
Value
$4.16
$5.12
52-Week Range:
Value
$3.03
$14.80

Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile

Name
Name
Titan Pharmaceuticals Inc De
Name
Phone
(650) 244-4990
Name
Address
400 OYSTER POINT BLVD, SAN FRANCISCO
Name
Employee
4
Name
Twitter
@titanpharma
Name
Next Earnings Date
2024-06-28
Name
Latest SEC Filings
Name
TTNP's Discussions on Twitter

Compare TTNP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TTNP
Titan Pharmaceuticals Inc De
4.65 4.21M 61,000 -5.46M -6.76M -6.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-26-19 Initiated Maxim Group Buy
Nov-10-17 Downgrade ROTH Capital Buy → Neutral

Titan Pharmaceuticals Inc De Stock (TTNP) Latest News

pulisher
Jun 04, 2025

Titan Medical (NASDAQ:TMDIF) Stock Price Down 2.4% – Here’s Why - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Merger Alert: Titan Pharmaceuticals Takes Major Step Toward TalenTec Combination with Critical SEC Filing - Stock Titan

Jun 03, 2025
pulisher
May 29, 2025

Biotech to AI: Bionoid Pharma Makes Bold Pivot with New Identity as AI Maverick Intel - Stock Titan

May 29, 2025
pulisher
May 22, 2025

Biotech Rising Star Conduit Pharmaceuticals Gets Green Light for Nasdaq Capital Market Transfer - Stock Titan

May 22, 2025
pulisher
May 21, 2025

Petros Pharmaceuticals Faces NASDAQ Delisting Despite $10M Cash Position, Plans Appeal - Stock Titan

May 21, 2025
pulisher
May 21, 2025

Conduit Pharmaceuticals Secures Future on Nasdaq: Clears Both Bid Price and Equity Hurdles - Stock Titan

May 21, 2025
pulisher
May 16, 2025

Conduit Pharma Sets 15:1 Reverse Split: Shares Drop to 755,900 Starting May 20 - Stock Titan

May 16, 2025
pulisher
May 16, 2025

Biotech Company Makes Bold Leap into AI: Bionoid Pharma Rebrands as AI Maverick Intel - Stock Titan

May 16, 2025
pulisher
May 15, 2025

HOPE Therapeutics Lands $7.8M Deal to Build National Mental Health Network with Ketamine Treatment Centers - Stock Titan

May 15, 2025
pulisher
May 13, 2025

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan

May 13, 2025
pulisher
May 12, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 - Stock Titan

May 12, 2025
pulisher
May 09, 2025

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - Stock Titan

May 09, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - Stock Titan

May 08, 2025
pulisher
May 07, 2025

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT - Stock Titan

May 07, 2025
pulisher
May 06, 2025

NRXP Reveals Major Mental Health Expansion Plans at Exclusive Mar-A-Lago Investor Event - Stock Titan

May 06, 2025
pulisher
May 05, 2025

Citius Pharmaceuticals Reveals Growth Strategy at Major Jefferies Healthcare Conference - Stock Titan

May 05, 2025
pulisher
May 02, 2025

Biotech Firm Terns Awards Massive 325,000 Share Options Package to New Key Hires - Stock Titan

May 02, 2025
pulisher
Apr 30, 2025

Generic Percocet Launch: Elite Pharmaceuticals Targets $317M Pain Management Market - Stock Titan

Apr 30, 2025
pulisher
Apr 29, 2025

Trump Executive Order Validates Petros' AI Technology Platform for Revolutionary Drug Access Reform - Stock Titan

Apr 29, 2025
pulisher
Apr 28, 2025

Heron Therapeutics Strengthens Leadership: Former Veloxis CEO Takes COO Role with Major Stock Package - Stock Titan

Apr 28, 2025
pulisher
Apr 24, 2025

Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan

Apr 24, 2025
pulisher
Apr 23, 2025

X4 Pharmaceuticals Strengthens Team with 450,000 Share Options Grant: Inside the Retention Plan - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

Major UK Retail Breakthrough: Sonoma's Natural Acne Treatment to Roll Out Across 1,200 Leading Pharmacies - Stock Titan

Apr 22, 2025
pulisher
Apr 21, 2025

Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan

Apr 21, 2025
pulisher
Apr 17, 2025

Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan

Apr 17, 2025
pulisher
Apr 16, 2025

Strategic Win: Phathom Taps 30-Year Pharma Veteran to Drive VOQUEZNA Commercial Success - Stock Titan

Apr 16, 2025
pulisher
Apr 14, 2025

US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga

Apr 14, 2025
pulisher
Apr 11, 2025

Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan

Apr 11, 2025
pulisher
Apr 11, 2025

Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

Keros Eyes Potential Sale: Board Weighs Strategic Options Amid Investor Interest - Stock Titan

Apr 10, 2025
pulisher
Apr 09, 2025

Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan

Apr 09, 2025
pulisher
Apr 08, 2025

Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan

Apr 08, 2025
pulisher
Apr 04, 2025

Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan

Apr 04, 2025
pulisher
Apr 04, 2025

Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan

Apr 04, 2025
pulisher
Apr 03, 2025

Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan

Apr 03, 2025
pulisher
Apr 03, 2025

Dogwood Therapeutics Saves Nasdaq Status: $17.5M Cash, Zero Debt After Major Financial Overhaul - Stock Titan

Apr 03, 2025
pulisher
Apr 02, 2025

Key Investor Update: Lexicon Pharma Takes Stage at Elite Needham Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Apr 01, 2025

Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan

Mar 28, 2025
pulisher
Mar 27, 2025

aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - Stock Titan

Mar 25, 2025
pulisher
Mar 23, 2025

$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan

Mar 23, 2025
pulisher
Mar 21, 2025

Eagle Pharmaceuticals Doubles Anti-Takeover Protection to $20 in Rights Plan Update - Stock Titan

Mar 21, 2025
pulisher
Mar 21, 2025

Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post

Mar 21, 2025
pulisher
Mar 20, 2025

Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

Petros Pharmaceuticals Targets $38B Self-Care Market with Game-Changing AI Drug Platform - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan

Mar 19, 2025
pulisher
Mar 17, 2025

NRx Pharmaceuticals Slashes Losses by 33% While Securing $300M+ Potential Deal - Stock Titan

Mar 17, 2025
pulisher
Mar 13, 2025

Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan

Mar 13, 2025

Titan Pharmaceuticals Inc De Stock (TTNP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Cap:     |  Volume (24h):